Exchange: NASDAQ·Updated 07:30 PM EST

FTXH News

News
all
press releases
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?
Smart Beta ETF report for FTXH
Zacks
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?
Smart Beta ETF report for FTXH
Zacks
More News
Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion, while its FY2025 revenue came in at $62.6 billion.
Stocktwits
Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.
Zacks
Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
Zacks
As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.
Zacks
JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.
Zacks
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Zacks

Advertisement|Remove ads.